Equities researchers at StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The firm has a market capitalization of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a 1-year low of $0.00 and a 1-year high of $0.00.
About Genocea Biosciences
Featured Stories
- Five stocks we like better than Genocea Biosciences
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- United Airlines Soars on Earnings Beat
- The 3 Best Retail Stocks to Shop for in August
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Investing in Commodities: What Are They? How to Invest in Them
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.